inflammatory diseases

Sandoz free to launch Humira biosimilar following AbbVie deal

https://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/

New data sets up potential new gastro use for J&J’s Stelara

https://pharmaphorum.com/news/new-data-sets-up-potential-new-gastro-use-for-jjs-stelara/

Merck & Co signs biosimilars deal for US veterans

https://pharmaphorum.com/news/merck-co-signs-biosimilars-deal-for-us-veterans/

Humira developer Winter among Nobel chemistry prize winners

https://pharmaphorum.com/news/humira-developer-winter-among-nobel-chemistry-prize-winners/

https://pharmaphorum.com/news/jj-trumpets-new-data-from-tremfya-as-psoriasis-market-braces-for-biosimilars/

AZ’s lupus drug fails in late-stage trial

https://pharmaphorum.com/news/astrazeneca-anifrolumab-fails-trial/

Celltrion hopes to outdo inflammatory disease rivals with SC infliximab

https://pharmaphorum.com/news/celltrion-hopes-to-outdo-inflammatory-disease-rivals-with-sc-infliximab/

https://pharmaphorum.com/news/mylan-to-market-lupins-enbrel-biosimilar-outside-us/

FDA rejects Teva/Celltrion biosimilars

https://pharmaphorum.com/news/fda-rejects-teva-celltrion-biosimilars/

1 2 3 4 5

Close in 10 seconds

Pharmaphorum.com

Search